NewsBenzingaライフコア・バイオメディカル、第3四半期EPSは1.08ドルの赤字で、予想を0.28ドル下回る。売上高は2,532.2万ドルで、予想2,669.9万ドルを下回る。 ライフコア・バイオメディカル、第3四半期EPSは1.08ドルの赤字で、予想を0.28ドル下回る。売上高は2,532.2万ドルで、予想2,669.9万ドルを下回る。 Benzinga 2026.11.04 12:24 (GMT+0) Open on Benzinga Other news Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120 Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22 Magic Empire Global Secures $100M Facility From Anyu International To Finance Its Timber Supply Chain Trading Operations Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24 Conference call: Stanley Black & Decker Sees FY 2026 Sales expected to be flat YoY
Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15
Magic Empire Global Secures $100M Facility From Anyu International To Finance Its Timber Supply Chain Trading Operations
